Community Access To Testing Program News Today

A recent commentary by Dr. Amesh Adalja in MedPage Today challenges the perception of COVID-19 as solely a respiratory virus, highlighting its broader impact on the body. This analysis questions the notion that COVID-19 should be managed like common respiratory infections, urging a closer look at vaccine effectiveness, the rise of long COVID, and the need for enhanced measures to curb the virus's spread. Let's explore the complexities of COVID-19 management and the pressing realities f...

An overview of updated CDC ACIP recommendations for COVID-19 vaccines available through commercial channels for the 2023-2024 season.

The US COVID public health emergency is over, which means COVID tests will be less available and affordable. Heres how to prioritize.

The complete primary series monovalent mRNA vaccines protect children aged three to five against symptomatic infection for up to four months.

In a recent Morbidity and Mortality Weekly Report (MMWR) published on the United States Center for Disease Control and Prevention (US-CDC) website, researchers analyzed data from the Increasing Community Access to Testing (ICATT), a nationwide pharmacy program run in the US for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.

New data for the bivalent COVID-19 booster shot shows that it cuts the risk in half for symptomatic infection from the now predominant Omicron subvariant, XBB.1.5.

Researchers discuss the efficacy of the bivalent COVID-19 vaccine against symptomatic infection with SARS-CoV-2 variants.

A regular series on the latest clinical studies from around the world – and what they mean ‘in practice’ – compiled and written by Clare GP Dr Ray

"The pandemic is over." No, it's very not.

A new study presents evidence suggestive of restored or increased efficacy from changing the formulation of COVID-19 vaccines to a bivalent one.